A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria: 1. Male or female patients ≥18 years of age at the time of informed consent 2. Part 1 Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor for which paclitaxel is considered appropriate treatment 3. Part 2 * Triple-negative and Stage IV inflammatory breast cancer * Recurrent ovarian cancer * Recurrent, metastatic or high-risk endometrial cancer * Advanced (stage III or IV), or recurrent gynecological carcinosarcoma * Homologous or heterologous type carcinosarcoma (malignant mixed Mullerian tumor \[MMMT\] allowed 4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤2 5. Able to provide an archival tumor tissue sample 6. Adequate organ function and bone marrow reserve 7. If a female of childbearing potential, must have a negative pregnancy test prior to enrollment 8. Patient must provide signed consent to participate in the study and is willing to comply with study-specific procedures Exclusion Criteria: 1. Received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose 2. Not recovered from prior-treatment toxicities to Grade ≤1 3. Peripheral neuropathy of any etiology \>Grade 1 4. Concurrent malignancy 5. Known active central nervous system (CNS) metastases 6. Use of systemic corticosteroids 7. Known retinal neovascularization, macular edema or macular degeneration 8. History or presence of clinically relevant cardiovascular abnormalities 9. QT interval corrected by Fridericia's formula (QTcF) \>450 ms in males or \>470 ms in females 10. Left ventricular ejection fraction (LVEF) \<50% at screening 11. Arterial thrombotic or embolic events 12. Venous thrombotic event 13. Active infection ≥Grade 3 14. Human immunodeficiency virus (HIV) or hepatitis C (HCV) infection only if taking medications excluded per protocol, active hepatitis B (HBV), or active HCV infection 15. Use of proton pump inhibitors 16. If female, the patient is pregnant or lactating 17. Major surgery 4 weeks prior to the first dose of study drug 18. Malabsorption syndrome or other illness which could affect oral absorption 19. Known allergy or hypersensitivity to any component of rebastinib or any of its excipients. 20. Any other clinically significant comorbidities